A chromatin modifier genetic screen identifies SIRT2 as a modulator of response to targeted therapies through the regulation of MEK kinase activity

MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling

(2012) Sidong Huang et al.   CELL

The Histone Deacetylase SIRT6 Is a Tumor Suppressor that Controls Cancer Metabolism

(2012) Carlos Sebastián et al.   CELL

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

(2012) Anirudh Prahallad et al.   NATURE

SIRT2 Maintains Genome Integrity and Suppresses Tumorigenesis through Regulating APC/C Activity

(2011) Hyun-Seok Kim et al.   CANCER CELL

Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder

(2011) Yaoting Gui et al.   NATURE GENETICS

Targeting the epigenome for treatment of cancer

(2011) E-J Geutjes et al.   ONCOGENE

DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors

(2011) Y. Jiao et al.   SCIENCE

Mechanisms of leukemogenesis by MLL fusion proteins

(2010) Rolf Marschalek   BRITISH JOURNAL OF HAEMATOLOGY

MLL fusions: Pathways to leukemia

(2010) Han Liu et al.   CANCER BIOLOGY & THERAPY

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

(2010) Sreenath V. Sharma et al.   CELL

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

(2010) Wendy De Roock et al.   LANCET ONCOLOGY

ARID1AMutations in Endometriosis-Associated Ovarian Carcinomas

(2010) Kimberly C. Wiegand et al.   NEW ENGLAND JOURNAL OF MEDICINE

Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma

(2010) Siân Jones et al.   SCIENCE

ZNF423 Is Critically Required for Retinoic Acid-Induced Differentiation and Is a Marker of Neuroblastoma Outcome

(2009) Sidong Huang et al.   CANCER CELL

Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer

(2009) Jolien Tol et al.   NEW ENGLAND JOURNAL OF MEDICINE